SynthesisJournal of cosmetic dermatology2026
The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.
Synthesis in Journal of cosmetic dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- The Relative Effects of Monotherapies for Psoriatic Nails: A Network Meta-Analysis Study.Journal of cosmetic dermatology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVarious treatments exist for nail psoriasis (NP). We determined the relative efficacy of various monotherapies through Bayesian network meta-analyses (NMAs).
methodsWe systematically reviewed the literature to identify eligible studies which-within the patient, intervention, comparator, outcome (PICO) context-determined the impact of biologic monotherapies on NP in terms of two outcome measures, namely, (1) the 16 to 24-week mean change in the Nail Psoriasis Severity Index (NAPSI) (i.e., outcome 1), and (2) the proportion who attained a Physician Global Assessment of fingernails (PGA-f) of "0" or "1" (i.e., "clear" or "almost clear") between 16 and 24 weeks (i.e., outcome 2). Our NMAs estimated the surface under the cumulative ranking curve (SUCRA) values and pairwise relative effects. We also determined relative effects of comparators that had never been compared for this condition, including "deucravacitinib 6mg daily", "risankizumab 150 mg at weeks 0, 4, 16", and "golimumab 2mg/kg at weeks 0, 4, then every 8 weeks". RESULTS AND
conclusionWe identified 22 active comparators; "tofacitinib 10 mg twice daily" was ranked most efficacious in terms of 16 to 24-week mean change in NAPSI (SUCRA = 99.71%)-while "ixekizumab 160 mg at week 0 followed by 80 mg every 4 weeks" was ranked most efficacious (SUCRA = 95.67%) for proportion attaining PGA-f of 0 or 1 (i.e., outcome 2). Our analyses produced comparative evidence for the relative efficacy of monotherapies with various agents, including biologics and non-biologics. Our findings would guide clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.